sivifene Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Sivifene is a small-molecule antineoplastic agent and immunomodulator that was under development in the 2000s by Tigris Pharmaceuticals as a topical treatment for cutaneous cancer metastases. It was specifically being investigated to treat high-grade squamous intraepithelial lesions (HSIL) associated with human papillomavirus (HPV) infection and invasive carcinomas of the anogenital area such as cervical, vaginal, and anal cancers. The drug reached phase II clinical trials prior to its discontinuation.   Wikipedia

Chemistry

  • SMILES: O=[N+]([O-])c1ccc(NN=C(c2ccc(O)cc2)c2ccc(O)cc2)c([N+](=O)[O-])c1
  • InChIKey: YOQPCWIXYUNEET-UHFFFAOYSA-N
  • Mol. Mass: 394.34
  • ALogP: 3.78
  • ChEMBL Molecule:
    sivifene  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone | a007 | a 007 | a-007 | sivifene

Organizations (28)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Cervical Intraepithelial Neoplasia (Phase 2)

HIV Infections (Phase 1)

Lymphoproliferative Disorders (Phase 1)

Sarcoma, Kaposi (Phase 1)

Uterine Cervical Dysplasia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue